MBRX Moleculin Biotech, Inc.
Price Chart
Executive Summary
Moleculin Biotech announced results from an independent market landscape assessment for its lead drug Annamycin in relapsed/refractory AML. Oncologists reported an average likelihood-to-prescribe score of 6 out of 7, citing deep remissions, transplant-bridging potential, biomarker-agnostic use, and reduced cardiotoxicity. Payers also viewed Annamycin as a potentially meaningful value proposition. The filing is a non-financial, qualitative update that provides third-party validation of commercial interest but contains no new clinical data or financial figures.
Actionable Insight
The strong physician intent-to-prescribe score (6/7) and payer support are positive signals for potential commercial adoption, but the research is explicitly directional and non-predictive. Monitor for upcoming clinical data from the MIRACLE Phase 2b/3 trial (MB-108) and any financing updates, as the company requires significant additional capital with no committed financing.
Key Facts
- Independent market research found hematologist-oncologists reported an average likelihood to prescribe Annamycin of 6 out of 7.
- Physicians cited complete remission rates, MRD-negative responses, transplant-bridging potential, biomarker-agnostic applicability, and reduced cardiotoxicity as key adoption drivers.
- Payers indicated Annamycin's efficacy, safety, and broad applicability could support a compelling value proposition.
- The research included academic and community hematologist-oncologists, medical oncologists, pediatric AML specialists, hospital administrators, and insurers.
- The filing explicitly notes the research is 'directional, not predictive' and 'does not support statistical generalization' due to its small, non-representative sample.
Financial Impact
No financial figures provided. The filing is a qualitative market research update with no revenue, earnings, or guidance data.
Risk Factors
- The market research is qualitative with a small, non-representative sample and explicitly stated as not supporting statistical generalization.
- Moleculin requires significant additional financing with no commitments to conduct its clinical trials as described.
- No new clinical efficacy or safety data was released — the assessment is based on previously reported results.
- The company has a $13M market cap and is pre-revenue, making it highly dependent on future capital raises and clinical trial outcomes.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-019660 |
| Exhibit: ex_972741.htm | 0001437749-26-019660 |
| Document: 0001437749-26-019660-index-headers.html | 0001437749-26-019660 |
| Document: 0001437749-26-019660-index.html | 0001437749-26-019660 |
| Document: 0001437749-26-019660.txt | 0001437749-26-019660 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
1d ago
|
8-K
| $2.58 awaiting T+5 | awaiting T+5 | — | $2.40 (−6.98%) |
|
May 29, 2026
8d ago
|
8-K
| $2.79 $2.46 | ▼ −11.83% | ▼ −11.54% | $2.40 (−13.98%) |
|
May 26, 2026
11d ago
|
8-K
| $2.45 $2.64 | ▲ +7.76% | ▲ +6.67% | $2.40 (−2.04%) |
|
May 22, 2026
15d ago
|
8-K
| $2.45 $2.64 | ▲ +7.76% | ▲ +6.67% | $2.40 (−2.04%) |
|
May 15, 2026
22d ago
|
8-K
| $2.11 $2.39 | ▲ +13.27% | ▲ +12.31% | $2.40 (+13.74%) |
|
May 15, 2026
22d ago
|
Press Release
| $2.11 $2.39 | ▼ −13.27% | ▼ −12.31% | $2.40 (−13.74%) |
|
May 13, 2026
24d ago
|
8-K
| $2.14 $2.35 | ▲ +9.81% | ▲ +10.97% | $2.40 (+12.15%) |
|
May 12, 2026
25d ago
|
8-K
| $2.34 $2.09 | ▼ −10.68% | ▼ −10.76% | $2.40 (+2.56%) |
|
May 8, 2026
29d ago
|
8-K
| $2.47 $2.20 | ▼ −10.93% | ▼ −12.39% | $2.40 (−2.83%) |
|
Apr 23, 2026
6w ago
|
8-K
| $2.54 $2.51 | ▼ −1.18% | ▼ −2.66% | $2.40 (−5.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access